Rothman KJ. The growing rift between epidemiologists and their data. Eur J Epidemiol. 2017 Oct;32(10):863-5. doi: 10.1007/s10654-017-0314-3
Rothman KJ. Disengaging from statistical significance - Commentary. Eur J Epidemiol. 2016 May;31(5):443-4. doi: 10.1007/s10654-016-0158-2
Moloney R, Mohr P, Hawe E, Shah K, Garau M, Towse A. Payer perspectives on future acceptability of comparative effectiveness and relative effectiveness research. Int J Technol Assess Health Care. 2015 Jan;31(1-2):90-8. doi: 10.1017/S0266462315000203
Mauskopf J, Chirila C, Masaquel C, Boye KS, Bowman L, Birt J, Grainger D. Relationship between financial impact and coverage of drugs in Australia. Int J Technol Assess Health Care. 2013 Jan 1;29(1):92-100.
Mauskopf J, Walter J, Birt J, Bowman L, Copley-Merriman C, Drummond M. Differences among formulary submission guidelines: implications for health technology assessment. Int J Technol Assess Health Care. 2011 Jul 1;27(3):261-70.
Rothman KJ, Stein Z, Susser M. Rebuilding bridges: what is the real role of social class in disease occurrence? Eur J Epidemiol. 2011 Jun;26(6):431-2.